Companies in #Vascular Access for Dialysis
Found 1 company operating in this sector.
Humacyte is a clinical-stage biotechnology company developing a pipeline of bioengineered human tissues and blood vessels using its proprietary LifePod platform and other regenerative-medicine manufacturing technologies. The lead product, ATEV (Acellular Tissue Engineered Vessel), is a first-in-class bioengineered blood vessel that has shown superiority in female dialysis-access patients in the V012 Phase 3 study (data June 2026), with a supplemental BLA filing planned in H2 2026. The company completed a 47.6M-share underwritten public offering in June 2026.